How fast should the preliminary results of medical research be disseminated and adopted into clinical practice? In this issue of the Journal, Giordano et al. ( 1 ) provide an example of moving fast. They describe the substantial increase in use of taxane chemotherapy for women with node-positive breast cancer in the year following the presentation of the Cancer and Leukemia Group B (CALGB) 9344 study at the 1998 American Society of Clinical Oncology (ASCO) meeting -nearly 5 years before publication of the results in a peer-reviewed journal.
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Moving fast is appealing. It means being on the cutting edge of medicine. It means bringing new hope to patients. There is a presumption that newer treatments are better than older ones. And all sorts of forces encourage the rapid adoption of new, so-called breakthrough treatments and technologies, including investigators with professional and fi nancial interests, pharmaceutical companies, an uncritical news media, aggressive disease advocacy groups, and desperate patients with progressive disease and no good options.
The taxane story supports the idea that moving fast can benefi t patients: Women with early breast cancer did not have to wait 5 years to get access to a useful treatment that has become a standard of care. The results presented at the 1998 ASCO meetingreleased at the recommendation of the study's data safety and monitoring board ( 1 ) -came from a well-done, large (more than 3000 women), multicenter randomized trial. The investigators found a small but real benefi t in a fundamentally important outcome -overall survival ( 2 ) . The meeting presentation also clearly reported the associated harms (e.g., grade 3 or greater toxicities such as transient myelosuppression [21%], neuropathy [5%], and pain [5%]). Fortunately, things worked out well. The interim results in the 1998 meeting report (97% of women in the taxane plus standard chemotherapy group and 95% of those in the standard chemotherapy group were alive at 18 months) closely mirrored the fi nal results published in 2003 (80% versus 77% were alive at 5 years) ( 1 ) . But the story might have had a very different ending: The early benefi t might not have held up in the longer term, and more harm might have emerged over time. The investigators and the patients were lucky.
The point is that moving fast is a gamble. When preliminary fi ndings turn out to be true, patients benefi t. When the fi ndings are not true, patients get hurt: They are exposed to ineffective or harmful treatments, or they forgo good alternatives.
The story of gefi tinib (Iressa) demonstrates the other side of the coin -a case where the adoption of preliminary results was a mistake. Unlike the taxane results, which were preliminary in time (i.e., the interim results were disseminated before publication of any results in a peer-reviewed journal article), Iressa is a story about results from a study that was preliminary in terms of design (i.e., a small, hypothesis-generating study using a surrogate outcome). Gefi tinib is a drug developed for the treatment of Ideally, physicians would never have to rely on preliminary research; they would have timely access to a complete report published in a peer-reviewed journal or to the results of defi nitive clinical trials. But in reality, preliminary research -and its enthusiastic dissemination -is here to stay.
Fortunately, there are ways to improve the dissemination of preliminary results. One way is for the organizers of scientifi c meetings to make more complete information available by posting on their Web site the actual meeting presentations, not just the published abstracts. Indeed, as mentioned by Giordano et al. ( 7 ) , ASCO has done so since 1999. Another approach is for meeting organizers to establish the expectation that major presentations be published at (or near) the time of the meeting. The nearly 5 years between presentation of the interim results of the CALGB 9344 trial at the ASCO meeting and publication of a full report in a peer-reviewed journal is unreasonable. If interim results are important enough to act on, a peer-reviewed publication is necessary. Because meeting organizers and medical journal editors share a common interest in getting important research out to the larger scientifi c community, it makes sense for them to work together to coordinate the presentation, review, and publication processes.
Furthermore, to routinely highlight the cautions about making inferences from intrinsically limited studies, meeting and journal abstracts (as well as the accompanying press releases) should include a " Caution " or " Limitation " header. Findings presented at scientifi c meetings may change substantially by the time they are published in a peer-reviewed journal, and many may never be published at all ( 8 , 9 ) . Clear and prominent cautions would serve not only clinicians but the news media as well. Although news stories about preliminary research are common, they rarely note important cautions, and the public may consequently be misled about the validity and relevance of the science ( 10 ) .
Regardless of what happens on the dissemination side, physicians need to approach preliminary research cautiously. Figure 1 provides a series of questions to help clinicians decide whether to encourage patients to gamble on preliminary results. First, did the research show an important clinical benefi t? By " clinical benefi t, " we mean interventions that affect how patients feel or function or whether they survive, as opposed to surrogate outcomes such as a change in tumor size or lab fi ndings. The patient's clinical state matters a lot. Patients who feel well or have a good prognosis already (i.e., with standard treatment) should demand more benefi t than patients who are sick or dying. Second, are there important downsides to using the new regimen? Judgments about benefi t need to be made in the context of harm. Important side effects may be acceptable in exchange for a clinically meaningful benefi t. But even small harms may outweigh any benefi t in a surrogate outcome. Third, how strong is the evidence for the fi ndings? Results from large, long-term randomized trials are more compelling than results from small trials or controlled observational studies and much more so than the results of a case series. Fourth, how does the new research fi t with prior work? Contradictory fi ndings are generally an indication for caution; however, the fi rst good randomized trial data may be suffi cient to trump a body of observational work [as occurred with regard to hormone replacement therapy with the publication of the Women's Health Initiative trial ( 11 ) ]. Finally, do effective treatment alternatives exist? It makes little sense to risk exposure to a new, therapeutically equivalent drug when safe and effective alternatives with longer track records are available.
Physicians are confronted with preliminary research fi ndings all the time. To decide whether the fi ndings are good enough to change practice, they must be able to answer some fundamental questions. The most basic question, of course, is what is the rush?
